Background: Malignant peritoneal mesothelioma (MPM) is a rare disease characterized by atypical symptoms, difficult diagnosis, variable course and poor prognosis, and it develops mainly in elderly individuals. The authors aimed to identify the clinical-pathological characteristics, prognosis, and prognostic factors in elderly [ malignant … [Read more...]
Biphasic Peritoneal Mesothelioma: A Lethal Clinical Entity
Abstract: Mesotheliomas are a rare malignancy of the serosal membrane. Mainly it affects the pleural surfaces followed by the second most common location, “peritoneum.” The disease follows an aggressive pattern of spread, and by the time the diagnosis is established, the condition significantly spreads to distant locations. Diagnosis of malignant … [Read more...]
Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study
Introduction: Malignant mesothelioma (MM) is an aggressive cancer that primarily arises from the pleura (MPM) or peritoneum (MPeM), mostly due to asbestos exposure. This study reviewed the Dutch population-based incidence, treatment and survival since the national ban on asbestos in 1993. Materials and methods: Patients with MPM or MPeM … [Read more...]
Drug Combo Promising in Rare Mesothelioma
A combination of atezolizumab (Tecentriq) and bevacizumab appeared effective and safe in patients with advanced malignant peritoneal mesothelioma, according to results from a small single-arm trial. The combination achieved an objective response rate (ORR) of 40% in patients who had progressed on or were resistant to prior platinum-pemetrexed … [Read more...]
Osteopontin, GLUT1 and Ki-67 expression in malignant peritoneal mesothelioma: prognostic implications
Background: Malignant peritoneal mesothelioma is the most common primary peritoneal neoplasm. The only universally recognised pathological prognostic factor is histopathological subtype. Prognostic markers based on patient features and clinical stages have been disappointing. Aims: To assess the prognostic role of several clinicopathological … [Read more...]
Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma
Introduction: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is an accepted treatment for peritoneal mesothelioma. In this study, we evaluated [ quality of life (QOL) ] after [ hyperthermic intraperitoneal chemotherapy (HIPEC) ] for peritoneal mesothelioma. Methods: This was a prospective study performed after … [Read more...]
50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience
Background: The most common sites of malignant mesothelioma are the pleura and peritoneum, but little is known about the incidence, prognosis, or treatment of patients with disease in both cavities. Previous series suggest that multimodality treatment improves overall survival for pleural or peritoneal disease, but studies typically exclude [ … [Read more...]
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations
Abstract: Malignant peritoneal mesothelioma (MPM) is a rare, aggressive malignancy that typically presents with vague symptoms, ascites, and/or diffuse peritoneal studding. Despite findings of advanced disease within the peritoneal cavity, spread beyond the abdomen is uncommon. Although advances in systemic chemotherapy have been made, … [Read more...]
50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience
Background: The most common sites of malignant mesothelioma are the pleura [ i.e., pleural mesothelioma ] and peritoneum [ i.e., peritoneal mesothelioma ], but little is known about the incidence, prognosis, or treatment of patients with disease in both cavities…. Despite limitations, this investigation is the only study to broadly examine … [Read more...]